Supplemental Material from JAAD Original Article Titled: Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6-months: a prospective analysis in the Corrona Psoriasis Registry

This data was collected from patients enrolled in CorEvitas’ Psoriasis Registry from April 2015 through June 2020.
Supplemental Table 1: Proportion of patients achieving BSA≤1% and IGA0/1 by drug class and metabolic comorbid disease.
Supplemental Table 2. Odds of achieving BSA≤1 and IGA0/1 by drug class and metabolic comorbid disease.

本数据集源于2015年4月至2020年6月间注册于CorEvitas银屑病登记处的患者。补充表1：按药物类别和代谢性合并疾病分类的患者达到体表面积≤1%及IGA0/1比例。补充表2：按药物类别和代谢性合并疾病分类的患者实现体表面积≤1%及IGA0/1的几率。